title: Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.
abstract: The favorable outcome of the treatment of a disease is influenced by the adherence to therapy. Our objective was to assess factors associated with adherence to treatment of patients included in a clinical trial of equivalence between the standard and alternative treatment schemes with meglumine antimoniate (MA) in the treatment of cutaneous leishmaniasis (CL), in the state of Rio de Janeiro. Between 2008 and 2011, 57 patients with CL were interviewed using a questionnaire to collect socioeconomic data. The following methods were used for adherence monitoring: counting of vial surplus, monitoring card, Morisky test and modified Morisky test (without the question regarding the schedule); we observed 82.1% (vial return), 86.0% (monitoring card), 66.7% (Morisky test) and 86.0% (modified Morisky test) adherence. There was a strong correlation between the method of vial counting and the monitoring card and modified Morisky test. A significant association was observed between greater adherence to treatment and low dose of MA, as well as with a lower number of people sleeping in the same room. We recommend the use of the modified Morisky test to assess adherence to treatment of CL with MA, because it is a simple method and with a good performance, when compared to other methods.
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Madelon Novato
authors: MN
authors: Ribeiro
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Maria Inês Fernandes
authors: MI
authors: Pimentel
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Armando de Oliveira
authors: Ade O
authors: Schubach
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Raquel de Vasconcellos Carvalhães de
authors: Rde V
authors: Oliveira
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: José Liporage
authors: JL
authors: Teixeira
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Madson Pedro da Silva
authors: MP
authors: Leite
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Monique
authors: M
authors: Fonseca
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Ginelza Peres Lima dos
authors: GP
authors: Santos
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Mariza Matos
authors: MM
authors: Salgueiro
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Erica de Camargo
authors: Ede C
authors: Ferreira e Vasconcellos
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Marcelo Rosandiski
authors: MR
authors: Lyra
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Mauricio Naoto
authors: MN
authors: Saheki
authors: Instituto de Pesquisas Evandro Chagas, IPEC/FIOCRUZ, Rio de Janeiro, RJ, Brazil.
authors: Claudia Maria
authors: CM
authors: Valete-Rosalino
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage*; D010349:Patient Compliance / Q000706:statistics & numerical data*; D012959:Socioeconomic Factors; D055815:Young Adult
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate